Anne-Françoise Dillies

Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study

Caroline Charlier, Élodie Perrodeau, Alexandre Leclercq et al. · The Lancet Infectious Diseases · 2017 · 556 citations · Full text

Prognostic Factors, Foodborne Illness, Clinical Features +6

Phase II Study of Sunitinib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: GORTEC 2006-01

Jean‐Pascal Machiels, Stéphanie Henry, Sylvie Zanetta et al. · Journal of Clinical Oncology · 2009 · 169 citations · Full text

Oncologic Imaging, Sunitinib Monotherapy, Dce-mri Monitoring +14

Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study

J. Guigay, Jérôme Fayette, Anne-Françoise Dillies et al. · Annals of Oncology · 2015 · 145 citations · Full text

Neoadjuvant Therapy, Medicine, Pathology +7

Immunonutrition improves functional capacities in head and neck and esophageal cancer patients undergoing radiochemotherapy: A randomized clinical trial

M.-P. Vasson, Jérémie Talvas, Olivier Perche et al. · Clinical Nutrition · 2013 · 77 citations

Randomized Clinical Trial, Esophageal Cancer Patients, Functional Capacities +13

NISCAHN: A phase II, multicenter nonrandomized trial aiming at evaluating nivolumab (N) in two cohorts of patients (pts) with recurrent/metastatic (R/M) salivary gland carcinoma of the head and neck (SGCHN), on behalf of the Unicancer Head & Neck Group.

Jérôme Fayette, Caroline Even, Laurence Digue et al. · Journal of Clinical Oncology · 2019 · 58 citations

Non-acc Pts, Phase Ii, Neck Group +15